Kanazawa Medical University and Eli Lilly and Company (Headquarters: Indianapolis, USA) signed a joint research agreement on April 2016, 4 for a new treatment for intractable gastric cancer.In a joint research between Professor Kazuo Yasumoto and Eli Lilly, Department of Oncology, Kanazawa Medical University, we will conduct research on diffuse gastric cancer, which is an intractable gastric cancer for which there is currently no effective treatment.
Kanazawa Medical University has elucidated the mechanism of new cancer onset and progression that leads to treatment from multiple animal models of diffuse gastric cancer in previous studies.Through joint research with Eli Lilly, we plan to confirm the effectiveness of the company's clinical compounds and lead to the early realization of new treatments for intractable gastric cancer.
In September 2015, Eli Lilly held a matching event for drug discovery joint research focusing on Japan.Recruiting drug discovery seeds in 9 areas such as cancer, matching the conditions of "being able to be first-in-class" and "having a proven model system and having some kind of hit or lead candidate is even more desirable" We have been discussing with Kanazawa Medical University to conclude a joint research contract.
